Paladin Labs Announces the Canadian Launch of DigiFab™ Digoxin Immune Fab (Ovine)
Paladin Labs Inc. has announced the Canadian launch of DigiFab™ Digoxin Immune Fab (Ovine).
DigiFab™ is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose.
There are approximately 1.6 million digoxin prescriptions written annually in Canada.
Digoxin is known to have a narrow therapeutic window and patients can easily move from a therapeutic to toxic dose through excessive dosing, slow elimination and metabolism or through interactions with other drugs.
Digoxin toxicity can cause potentially life-threatening heart rhythm disturbances.
Paladin acquired the exclusive Canadian rights to market and sell DigiFab™ from BTG International Inc., in February 2010.